ImmuCell Corporation (ICCC)
NASDAQ: ICCC · Real-Time Price · USD
8.92
+0.66 (7.99%)
May 15, 2026, 4:00 PM EDT - Market closed
ImmuCell Revenue
ImmuCell had revenue of $10.36M in the quarter ending March 31, 2026, with 28.39% growth. This brings the company's revenue in the last twelve months to $29.93M, up 9.64% year-over-year. In the year 2025, ImmuCell had annual revenue of $27.64M with 4.34% growth.
Revenue (ttm)
$29.93M
Revenue Growth
+9.64%
P/S Ratio
2.70
Revenue / Employee
$410,059
Employees
73
Market Cap
80.70M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 27.64M | 1.15M | 4.34% |
| Dec 31, 2024 | 26.49M | 9.02M | 51.63% |
| Dec 31, 2023 | 17.47M | -1.10M | -5.90% |
| Dec 31, 2022 | 18.57M | -675.00K | -3.51% |
| Dec 31, 2021 | 19.24M | 3.90M | 25.43% |
| Dec 31, 2020 | 15.34M | 1.62M | 11.80% |
| Dec 31, 2019 | 13.72M | 2.74M | 24.91% |
| Dec 31, 2018 | 10.99M | 555.20K | 5.32% |
| Dec 31, 2017 | 10.43M | 887.14K | 9.30% |
| Dec 31, 2016 | 9.54M | -684.74K | -6.69% |
| Dec 31, 2015 | 10.23M | 2.63M | 34.64% |
| Dec 31, 2014 | 7.60M | 1.59M | 26.46% |
| Dec 31, 2013 | 6.01M | 617.24K | 11.45% |
| Dec 31, 2012 | 5.39M | 278.80K | 5.45% |
| Dec 31, 2011 | 5.11M | 724.94K | 16.53% |
| Dec 31, 2010 | 4.39M | -119.56K | -2.65% |
| Dec 31, 2009 | 4.51M | -122.55K | -2.65% |
| Dec 31, 2008 | 4.63M | -6.21M | -57.31% |
| Dec 31, 2007 | 10.84M | 1.73M | 19.04% |
| Dec 31, 2006 | 9.11M | -109.26K | -1.19% |
| Dec 31, 2005 | 9.22M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 66.16M |
| Gossamer Bio | 55.54M |
| Atara Biotherapeutics | 23.14M |
| Alterity Therapeutics | 4.43M |
| eXoZymes | -700.00 |
ICCC News
- 2 days ago - ImmuCell Earnings Call Transcript: Q1 2026 - Transcripts
- 3 days ago - ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026 - GlobeNewsWire
- 10 days ago - ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026 - GlobeNewsWire
- 4 weeks ago - ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors - GlobeNewsWire
- 5 weeks ago - ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results - GlobeNewsWire
- 2 months ago - ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board - GlobeNewsWire
- 2 months ago - ImmuCell Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025 - GlobeNewsWire